|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer Clin. 61:69–90.
2011. View Article : Google Scholar
|
|
2
|
Wolf S, Haase-Kohn C and Pietzsch J:
S100A2 in carcinogenesis: a friend or a foe? Amino Acids.
41:849–861. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mueller A, Schäfer BW, Ferrari S, Weibel
M, Makek M, Höchli M and Heizmann CW: The calcium-binding protein
S100A2 interacts with p53 and modulates its transcriptional
activity. J Biol Chem. 280:29186–29193. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lapi E, Iovino A, Fontemaggi G, Soliera
AR, Iacovelli S, Sacchi A, Rechavi G, Givol D, Blandino G and
Strano S: S100A2 gene is a direct transcriptional target of p53
homologues during keratinocyte differentiation. Oncogene.
25:3628–3637. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsai ST, Jin YT, Tsai WC, Wang ST, Lin YC,
Chang MT and Wu LW: S100A2, a potential marker for early recurrence
in early-stage oral cancer. Oral Oncol. 41:349–357. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nagy N, Brenner C, Markadieu N, Chaboteaux
C, Camby I, Schäfer BW, Pochet R, Heizmann CW, Salmon I, Kiss R and
Decaestecker C: S100A2, a putative tumor suppressor gene, regulates
in vitro squamous cell carcinoma migration. Lab Invest. 81:599–612.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohuchida K, Mizumoto K, Miyasaka Y, Yu J,
Cui L, Yamaguchi H, Toma H, Takahata S, Sato N, Nagai E, Yamaguchi
K, Tsuneyoshi M and Tanaka M: Over-expression of S100A2 in
pancreatic cancer correlates with progression and poor prognosis. J
Pathol. 213:275–282. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartling B, Rehbein G, Schmitt WD, Hofmann
HS, Silber RE and Simm A: S100A2-S100P expression profile and
diagnosis of non-small cell lung carcinoma: impairment by advanced
tumour stages and neoadjuvant chemotherapy. Eur J Cancer.
43:1935–1943. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ito Y, Yoshida H, Tomoda C, Uruno T, Miya
A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K and Miyauchi A:
Expression of S100A2 and S100A6 in thyroid carcinomas.
Histopathology. 46:569–575. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sobin LH and Wittekind CH: TNM
Classification of Malignant Tumors. 6th edition. Hoboken NJ: John
Wiley & Sons; NJ: 2002
|
|
11
|
Zheng HC, Li XH, Hara T, Masuda S, Yang
XH, Guan YF and Takano Y: Mixed-type gastric carcinomas exhibit
more aggressive features and indicate the histogenesis of
carcinomas. Virchows Arch. 452:525–534. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng H, Takahashi H, Murai Y, Cui Z,
Nomoto K, Miwa S, Tsuneyama K and Takano Y: Pathobiological
characteristics of intestinal and diffuse-type gastric carcinoma in
Japan: an immunostaining study on the tissue microarray. J Clin
Pathol. 60:273–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo J, Zhu Y, Yang G, Gong L, Wang B and
Liu H: Loss of Reprimo and S100A2 expression in human gastric
adenocarcinoma. Diagn Cytopathol. 39:752–757. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee OJ, Hong SM, Razvi MH, Peng D, Powell
SM, Smoklin M, Moskaluk CA and El-Rifai W: Expression of
calcium-binding proteins S100A2 and S100A4 in Barrett's
adenocarcinomas. Neoplasia. 8:843–850. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kwon YW, Chang IH, Kim KD, Kim YS, Myung
SC, Kim MK and Kim TH: Significance of S100A2 and S100A4 expression
in the progression of prostate adenocarcinoma. Korean J Urol.
51:456–462. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cao LY, Yin Y, Li H, Jiang Y and Zhang HF:
Expression and clinical significance of S100A2 and p63 in
esophageal carcinoma. World J Gastroenterol. 15:4183–4188. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Imazawa M, Hibi K, Fujitake S, Kodera Y,
Ito K, Akiyama S and Nakao A: S100A2 overexpression is frequently
observed in esophageal squamous cell carcinoma. Anticancer Res.
25:1247–1250. 2005.PubMed/NCBI
|
|
18
|
Zheng HC, Xu XY, Yu M, Takahashi H, Masuda
S and Takano Y: The role of Reg IV gene and its encoding product in
gastric carcinogenesis. Hum Pathol. 41:59–69. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang YC: Geographic pathology of gastric
dysplasia in China. Semin Surg Oncol. 10:100–106. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wicki R, Franz C, Scholl FA, Heizmann CW
and Schäfer BW: Repression of the candidate tumor suppressor gene
S100A2 in breast cancer is mediated by site-specific
hypermethylation. Cell Calcium. 22:243–254. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rehman I, Cross SS, Catto JW, Leiblich A,
Mukherjee A, Azzouzi AR, Leung HY and Hamdy FC: Promoter
hyper-methylation of calcium binding proteins S100A6 and S100A2 in
human prostate cancer. Prostate. 65:322–330. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Feng G, Xu X, Youssef EM and Lotan R:
Diminished expression of S100A2, a putative tumor suppressor, at
early stage of human lung carcinogenesis. Cancer Res. 61:7999–8004.
2001.PubMed/NCBI
|
|
23
|
Zhang X, Hunt JL, Shin DM and Chen ZG:
Down-regulation of S100A2 in lymph node metastases of head and neck
cancer. Head Neck. 29:236–243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Suzuki F, Oridate N, Homma A, Nakamaru Y,
Nagahashi T, Yagi K, Yamaguchi S, Furuta Y and Fukuda S: S100A2
expression as a predictive marker for late cervical metastasis in
stage I and II invasive squamous cell carcinoma of the oral cavity.
Oncol Rep. 14:1493–1498. 2005.PubMed/NCBI
|
|
25
|
Matsumoto K, Irie A, Satoh T, Ishii J,
Iwabuchi K, Iwamura M, Egawa S and Baba S: Expression of S100A2 and
S100A4 predicts for disease progression and patient survival in
bladder cancer. Urology. 70:602–607. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matsubara D, Niki T, Ishikawa S, Goto A,
Ohara E, Yokomizo T, Heizmann CW, Aburatani H, Moriyama S, Moriyama
H, Nishimura Y, Funata N and Fukayama M: Differential expression of
S100A2 and S100A4 in lung adenocarcinomas: clinicopathological
significance, relationship to p53 and identification of their
target genes. Cancer Sci. 96:844–857. 2005. View Article : Google Scholar
|
|
27
|
Almadori G, Bussu F, Galli J, Rigante M,
Lauriola L, Michetti F, Maggiano N, Schafer BW, Heizmann CW,
Ranelletti FO and Paludetti G: Diminished expression of S100A2, a
putative tumour suppressor, is an independent predictive factor of
neck node relapse in laryngeal squamous cell carcinoma. J
Otolaryngol Head Neck Surg. 38:16–22. 2009.PubMed/NCBI
|
|
28
|
Lauriola L, Michetti F, Maggiano N, Galli
J, Cadoni G, Schäfer BW, Heizmann CW and Ranelletti FO: Prognostic
significance of the Ca(2+) binding protein S100A2 in laryngeal
squamous-cell carcinoma. Int J Cancer. 89:345–349. 2000.
|
|
29
|
Wang H, Zhang Z, Li R, Ang KK, Zhang H,
Caraway NP, Katz RL and Jiang F: Overexpression of S100A2 protein
as a prognostic marker for patients with stage I non-small cell
lung cancer. Int J Cancer. 116:285–290. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kyriazanos ID, Tachibana M, Dhar DK,
Shibakita M, Ono T, Kohno H and Nagasue N: Expression and
prognostic significance of S100A2 protein in squamous cell
carcinoma of the esophagus. Oncol Rep. 9:503–510. 2002.PubMed/NCBI
|
